Latest Breaking News On - மார்கோ பூர்ஸ்மா - Page 1 : comparemela.com

VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders

VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Noord hollandMarco boorsmaSanofi genzymeEli lillyCarlo incertiSander van deventerAlexander vosCompany board of directorsEuropean recovery programmeDutch venture initiativeBiogeneration venturesVectory therapeuticsAmsterdam science parkChief executive officerChief technology officerChief medical officer

VectorY Raises €31M in Seed Funding

VectorY Raises €31M in Seed Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

Noord hollandMarco boorsmaSanofi genzymeEli lillyCarlo incertiSander van deventerAlexander vosVectory therapeuticsAmsterdam science parkChief medical officerGeneral partnerநூற்த் ஹாலண்ட்மார்கோ பூர்ஸ்மாஎலி லில்லிசாண்டர் வேன் டெவெண்டேர்அலெக்சாண்டர் வாஸ்

Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies

Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies Targeting muscular and neurodegenerative disorders Amsterdam-based company seeded by Forbion Co-founded by highly experienced gene therapy technology and manufacturing team VectorY, a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, today announces its official launch. The Company has been operational since October 2020 and has established its laboratories and offices at the Amsterdam Science Park in The Netherlands. VectorY develops proprietary and partnered programs based on a novel AAV platform and innovative antibody-based targeted degradation technologies. The Company is creating a pipeline of innovative vectorized antibodies targeting muscular and CNS diseases, aimed at overcoming limitations of current therapies, specifically by improving delivery, durability and accessibility of targe

Noord hollandMarco boorsmaSanofi genzymeCarlo incertiBarbara sandersGenevieve wilsonAnthony newcombeKostenloser wertpapierhandelPavlina konstantinovaSander slootwegEuropean recovery programmeDutch venture initiativeAmsterdam science parkGeneral partnerOperating partnerChief medical officer